This trial will test if a combination of the drugs Vemurafenib and Metformin is safe for melanoma patients, and if it is more effective than Vemurafenib alone.
1 Primary · 4 Secondary · Reporting Duration: Duration of study (approximately 60 months)
Side Effects for
1 Treatment Group
Vemurafenib and Metformin
1 of 1
55 Total Participants · 1 Treatment Group
Primary Treatment: Vemurafenib · No Placebo Group · Phase 1 & 2
Who is running the clinical trial?
Age 18+ · All Participants · 15 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
- Cerezo, Michael, Tijana Tomic, Robert Ballotti, and Stéphane Rocchi. 2014. “Is It Time to Test Biguanide Metformin in the Treatment of Melanoma?”. Pigment Cell & Melanoma Research. Wiley. doi:10.1111/pcmr.12267.
- Cerezo M, Tomic T, Ballotti R, Rocchi S. Is it time to test biguanide metformin in the treatment of melanoma? Pigment Cell Melanoma Res. 2015 Jan;28(1):8-20. doi: 10.1111/pcmr.12267. Epub 2014 Jun 26.
- Jason Chesney 2012. "A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT01638676.
Frequently Asked Questions
In what scenarios is Vemurafenib typically employed?
"Vemurafenib is employed to tackle metastatic melanoma, as well as conditions such as non-small cell lung carcinoma and unresectable melanomas. It has also been found to be effective for exercise." - Anonymous Online Contributor
How many participants are involved in the research?
"Affirmative. Clinicaltrials.gov attests that recruitment for this medical study is still ongoing, having first been posted on July 1st 2012 and lastly edited on October 22nd 2021. The research is hoping to find 55 participants across a single site." - Anonymous Online Contributor
Is this investigation still open to recruitment of participants?
"The clinical trial is actively recruiting, as reported on the website for clinicaltrials.gov. It was made available to prospective participants on July 1st 2012 and has been updated with new information most recently in October of 2021." - Anonymous Online Contributor